Effectiveness of Infliximab for Refractory Nonischemic Cerebral Enhancing Foreign-Body Granulomatous Lesions After Endovascular Therapy
This article provides Class IV evidence that infliximab may offer potential benefit in patients with NICE lesions after EVT.
Authors
- Albert Aboseif (ORCID: https://orcid.org/0000-0001-5053-8544)
- Eoin P. Flanagan (ORCID: https://orcid.org/0000-0002-6661-2910)
- Andrew D. Smith (ORCID: https://orcid.org/0000-0003-3002-222X)
- Andrew B. McKeon (ORCID: https://orcid.org/0000-0001-6856-8143)
- Gina Perez-Giraldo (ORCID: https://orcid.org/0000-0002-8798-3753)
- Nathan T. Tagg (ORCID: https://orcid.org/0000-0002-7876-4807)
- Sean Joseph Pittock (ORCID: https://orcid.org/0000-0002-6140-5584)
- Robert D. Brown (ORCID: https://orcid.org/0000-0002-7065-8807)
- Farris Taha
Institutions
- Dartmouth College (US)
- Dartmouth–Hitchcock Medical Center (US)
- Medical University of South Carolina (US)
- Duke University (US)
- Washington University in St. Louis (US)
- Mayo Clinic in Arizona (US)
Publication Details
- Journal
- Neurology
- Published
- 2025-10-29
- DOI
- https://doi.org/10.1212/wnl.0000000000214345
- Primary Topic
- Hemostasis and retained surgical items
- Type
- article
- Field-Weighted Citation Impact
- 0.00